What is HC Wainwright's Estimate for ProKidney Q3 Earnings?

Key Points

• HC Wainwright lowered its Q3 2026 EPS estimate for ProKidney to a loss of $0.13 per share from $0.12, while maintaining a Buy rating and $12 price target.
• ProKidney recently reported a quarterly loss of $0.15 per share, missing the $0.14 consensus estimate, while revenue of $0.15 million also fell short of the $0.19 million forecast.
• Shares opened at $1.48, near the company’s 52-week low of $1.41; institutional investors own 51.59% of the stock, with several major firms increasing their positions.

ProKidney Corp. (NASDAQ:PROK - Free Report) - Stock analysts at HC Wainwright lowered their Q3 2026 earnings estimates for ProKidney in a report issued on Tuesday, August 11th. HC Wainwright analyst J. Pantginis now anticipates that the company will post earnings per share of ($0.13) for the quarter, down from their prior forecast of ($0.12). HC Wainwright currently has a "Buy" rating and a $12.00 target price on the stock. The consensus estimate for ProKidney's current full-year earnings is ($0.49) per share. HC Wainwright also issued estimates for ProKidney's Q4 2026 earnings at ($0.11) EPS, FY2026 earnings at ($0.52) EPS, FY2027 earnings at ($0.56) EPS, FY2028 earnings at ($0.55) EPS and FY2029 earnings at ($0.39) EPS.

ProKidney (NASDAQ:PROK - Get Free Report) last posted its earnings results on Monday, August 10th. The company reported ($0.15) earnings per share for the quarter, missing analysts' consensus estimates of ($0.14) by ($0.01). The company had revenue of $0.15 million for the quarter, compared to the consensus estimate of $0.19 million.

Several other research analysts have also recently issued reports on PROK. Wall Street Zen cut ProKidney from a "sell" rating to a "strong sell" rating in a research report on Saturday, May 16th. Weiss Ratings raised ProKidney from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Friday, July 10th. One analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $12.00.

ProKidney Stock Performance

Shares of PROK opened at $1.48 on Thursday. The firm has a market capitalization of $447.05 million, a P/E ratio of -2.69 and a beta of 1.66. ProKidney has a 52 week low of $1.41 and a 52 week high of $3.48. The stock has a 50 day moving average price of $1.71 and a two-hundred day moving average price of $1.88.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. AQR Capital Management LLC lifted its position in ProKidney by 106.4% in the 1st quarter. AQR Capital Management LLC now owns 52,570 shares of the company's stock worth $46,000 after buying an additional 27,098 shares during the last quarter. JPMorgan Chase & Co. boosted its holdings in shares of ProKidney by 3,024.9% during the second quarter. JPMorgan Chase & Co. now owns 1,668,642 shares of the company's stock worth $988,000 after purchasing an additional 1,615,243 shares during the period. Marshall Wace LLP purchased a new position in ProKidney during the 2nd quarter valued at about $274,000. Jane Street Group LLC purchased a new stake in ProKidney in the 2nd quarter worth approximately $350,000. Finally, Bank of America Corp DE grew its position in shares of ProKidney by 12.4% in the 2nd quarter. Bank of America Corp DE now owns 846,154 shares of the company's stock worth $501,000 after buying an additional 93,322 shares during the last quarter. 51.59% of the stock is owned by institutional investors.

About ProKidney

ProKidney, Inc NASDAQ: PROK is a clinical-stage biotechnology company focused on developing cell-based therapies for kidney diseases. The company’s research and development activities center on harnessing human-derived proximal tubule cells to address conditions such as acute kidney injury (AKI) and chronic kidney disease (CKD). By targeting the underlying cellular mechanisms of renal injury and dysfunction, ProKidney aims to offer novel regenerative medicine approaches that go beyond current supportive care options.

ProKidney’s lead programs utilize proprietary methods for isolating and expanding renal epithelial cells to create injectable therapeutic products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source